SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Rigel Pharmaceuticals, Inc. (RIGL)
An SI Board Since November 2000
Posts SubjectMarks Bans Symbol
566 39 0 RIGL
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
391Seeking Alpha: Rigel's Punishment May Prove Short-Sighted by: EP Vantage Octmopgcw-10/31/2008
390Citi: 27 October 2008 - 8 pages Rigel mopgcw-10/28/2008
389>>I guess the perception is that small molecules don't look any bettertuck-10/28/2008
388I guess the perception is that small molecules don't look any better than coscaram(o)uche-10/28/2008
387CS: Sell Off Overdone - Reiterate Outperform Conclusion: With the stock down ~4mopgcw-10/28/2008
386CS on the ACR meeting: Major Pharmaceuticals Market Weight C. Arnold ACR Day 1: mopgcw-10/27/2008
385I missed the very beginning and very end, but did not hear anything on the call mopgcw-10/27/2008
384lupus protocol ready to go, but not going to enroll until partner signs up. quescaram(o)uche-10/27/2008
383010 about 50% enrolled, 011 is about one-third enrolled. "Appears to be a scaram(o)uche-10/27/2008
382efficacy is positive, there is a small efficacy bump in the placebo group too thmopgcw-10/27/2008
381looks like a BP increase SE is showing up. Believe it can be treated with inhibmopgcw-10/27/2008
380CS: Rigel Pharmaceuticals Inc. (RIGL) Outperform [V] M. Aberman CP: US$ 24.90 TPmopgcw-9/18/2008
379Try this one and search for the abstract. abstractsonline.com Alternatively, tidos-9/16/2008
378Thank you! Already see much of interest, but the link yields (for me) "Objscaram(o)uche-9/15/2008
377Presentation abstract of PFE competitor's phase IIb: abstractsonline.com &idos-9/15/2008
376Citi: 26 August 2008 - 44 pages Rigel (RIGL) mopgcw-9/10/2008
375CS: Rigel Pharmaceuticals Inc. (RIGL) Outperform [V] M. Aberman CP: US$ 25.09 TPmopgcw-8/5/2008
374nothing here worth the time, just parking.... Br J Haematol. 2008 May;141(5):68scaram(o)uche-7/21/2008
373bkgd info..... The Lancet Early Online Publication, 16 July 2008 Comparison oscaram(o)uche-7/16/2008
372Leukemia. 2008 Jul 3. [Epub ahead of print] Tyrosine kinase inhibition in diffuscaram(o)uche-7/10/2008
371>> short interest was up 24% in the last reporting period and has doubled scaram(o)uche-6/24/2008
370Rigel Initiates Two Phase 2b Clinical Trials of R788 in Rheumatoid Arthritis Thumopgcw-6/12/2008
369I know a couple of physicians who both run a fund (one of the two) and advise otscaram(o)uche-6/3/2008
368and the stock down 7%....go figure.mopgcw-6/3/2008
367Folicular...... several patients at stable disease, appear to be resolving loscaram(o)uche-6/3/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News